18F FACBC an innovative imaging agent for the diagnosis of prostate cancer: a Phase III evaluation in recurrent prostate cancer

A new PET imaging agent, [18F]FACBC, is entering a Phase III clinical trial in men with recurrent prostate cancer—the first such PET imaging study run entirely in the UK. Current scans for prostate cancer often miss or misidentify recurrences, leaving doctors without clear guidance on where to treat. [18F]FACBC is a synthetic version of the amino acid leucine, which cancer cells take up in large amounts because of their high metabolic activity. By tracking where this tracer accumulates, PET scans could reveal tumours that standard imaging overlooks. If the trial succeeds, the agent could become a routine diagnostic tool, giving oncologists precise information about the location and extent of recurrent disease. That would allow them to target radiotherapy or surgery more accurately, sparing healthy tissue and improving outcomes. The project brings together seven UK clinical centres and GE Healthcare, positioning the country as a leader in this imaging technology. For patients, the immediate impact would be clearer answers and more effective treatment decisions after initial therapy fails.